• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by The Oncology Institute Inc.

    5/2/24 4:57:55 PM ET
    $TOI
    Medical/Nursing Services
    Health Care
    Get the next $TOI alert in real time by email
    DEFA14A 1 d793569ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant  ☒

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    The Oncology Institute, Inc.

    (Name of Registrant as Specified In Its Charter)

    NOT APPLICABLE

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     


      LOGO

      PROXY TABULATOR: P.O. BOX 8016, CARY, NC 27512-9903

     

     

     

    LOGO

     

      

    LOGO

     

    The Oncology Institute, Inc.

     

    Annual Meeting of Stockholders

     

    Thursday, June 13, 2024 11:00 AM, Pacific Time

     

    Annual Meeting to be held live via the internet - please visit www.proxydocs.com/TOI for more details.

     

    You must register to attend the Annual Meeting online and/or participate at www.proxydocs.com/TOI

     

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/TOI

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

     

    If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 3, 2024.

     

      

       LOGO    

      

    Scan QR for  

    digital voting  

     

     

     

    Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 13, 2024 For Stockholders of record as of April 15, 2024

     

    To order paper materials, use one of the following methods.

     

      LOGO

     

    Internet:

    www.investorelections.com/TOI

     

      LOGO

    Call:

    1-866-648-8133

     

      LOGO

    Email:

    [email protected]

     

    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

     

    LOGO

         

    Have the 12 digit control number located in the

    box above available when you access the

    website and follow the instructions.

    SEE REVERSE FOR FULL AGENDA      
      

     

    Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO   The Oncology Institute, Inc. Annual Meeting of Stockholders
     

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

        FOR ON PROPOSALS 1, 2 AND 3

     

     

     

    PROPOSAL

     

    1.    Election of nine directors.   
       1.01 Richard Barasch   
       1.02 Maeve O’Meara Duke   
       1.03 Brad Hively   
       1.04 Karen Johnson   
       1.05 Mohit Kaushal      
       1.06 Gabriel Ling   
       1.07 Anne McGeorge   
       1.08 Mark Pacala   
       1.09 Daniel Virnich   
    2.    Ratification of the appointment of BDO USA, P.C. as the independent registered public accounting firm of the Company for 2024.   
    3.    Approval, for the purposes of Nasdaq Listing Rule 5635, of the issuances of the maximum number of shares of Common Stock underlying our Secured Senior Convertible Notes and Warrants to purchase Common Stock.
    Get the next $TOI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TOI

    DatePrice TargetRatingAnalyst
    11/25/2025$5.00Buy
    Needham
    7/23/2025$8.00Outperform
    Noble Capital Markets
    7/16/2025$6.00Buy
    B. Riley Securities
    5/15/2025$7.00Buy
    BTIG Research
    2/26/2024$2.50Buy
    Jefferies
    9/14/2022$7.00Buy
    Guggenheim
    8/15/2022$10.00Buy
    Jefferies
    More analyst ratings

    $TOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    4/28/25 7:20:14 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Virnich Daniel bought $23,584 worth of shares (22,640 units at $1.04), increasing direct ownership by 3% to 724,363 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:50:27 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Medical Officer Podnos Yale bought $9,434 worth of shares (9,056 units at $1.04), increasing direct ownership by 13% to 79,049 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:48:39 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    SEC Filings

    View All

    The Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    1/12/26 8:00:43 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    1/7/26 5:02:33 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    12/1/25 4:30:53 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on The Oncology Institute with a new price target

    Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00

    11/25/25 8:00:05 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Noble Capital Markets initiated coverage on The Oncology Institute with a new price target

    Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00

    7/23/25 9:21:53 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    B. Riley Securities initiated coverage on The Oncology Institute with a new price target

    B. Riley Securities initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $6.00

    7/16/25 7:58:29 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook

    CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation revenue in 2026. This expected top-line increase reflects continued expansion of delegated contracts in Florida, the annualized impact of strong volumes in the Dispensary segment during the se

    1/12/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care

    DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates ("USNA" or the "Company"), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA's Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (

    1/9/26 4:45:26 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Leadership Promotions

    Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. These promotions reinforce TOI's continued focus on leading the way in value-based cancer care through further development of our technology-enabled care delivery platform as well as strengthening our mission-oriented culture supported by strong leadership. Rakesh Panda has more than 25 years of experience across IT, digital transformation, cybersecurity, and enterprise software develo

    1/9/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Stolper Mark

    3 - Oncology Institute, Inc. (0001799191) (Issuer)

    1/12/26 4:57:19 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Amendment: Chief Financial Officer Carter Robert Ross disposed of $895 worth of shares (244 units at $3.67), decreasing direct ownership by 0.10% to 235,125 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    1/6/26 4:30:02 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Carter Robert Ross sold $879 worth of shares (247 units at $3.56), decreasing direct ownership by 0.10% to 235,122 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    1/5/26 5:04:59 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Financials

    Live finance-specific insights

    View All

    The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

    CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended September 30, 2025 and updated its full year 2025 guidance. Recent Operational Highlights Fee-for-service revenue growth of 13% over Q3 2024, driven by continued organic growth performance in Florida and Oregon.Retail Pharmacy and Dispensary set fill records, contributing $75.9 million in revenue and $12.8 million in gross profit in Q3. Signed several new in-network MSO providers in the Florida market and opened our new TOI pharmacy

    11/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Third Quarter 2025 Earnings Release Date and Conference Call

    CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI),  a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2025 financial results after the market close on Thursday, November 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 1

    10/22/25 4:47:31 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

    CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025. Daniel Virnich, CEO of TOI, commented, "We delivered another strong quarter with over 20% year-over-year revenue growth. This was driven by exceptional performance in our pharmacy business, which grew over 40% year-over-year, as well as the addition of over 50,000 new capitated lives to our value-based business. We are also in the process of expanding our partnership into new geographic regions of Florida with a major

    8/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Oncology Institute Inc.

    SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    8/20/24 8:20:55 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form SC 13D/A filed by The Oncology Institute Inc. (Amendment)

    SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    1/2/24 5:06:50 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)

    SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

    7/10/23 10:20:11 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    The Oncology Institute Announces Resignation of Board Member Gabe Ling

    CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. "On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute's development," said Anne McGeorge, Chairman of the Board. "We appreciate the contributions he made throughout his time on the Board and the valua

    12/1/25 8:30:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Names Kristin England as Chief Administrative Officer

    CERRITOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that Kristin England has joined the organization as Chief Administrative Officer (CAO), effective July 7, 2025. In this newly established role, England will oversee Enterprise Central Business Operations and Technology Strategy and Enablement across TOI's expanding national footprint. England brings over two decades of leadership experience in healthcare management and operations, most recently serving as a senior executive within McKesson's US Oncology Network. There, she led high-performing teams focus

    7/14/25 4:05:25 PM ET
    $TOI
    Medical/Nursing Services
    Health Care